CTRI/2019/06/019936已完成2 期
An Open labelled non randomised Phase II comparative clinical trail to evaluate the therapeutic efficacy of POTTANAM (External therapy) and AAYIL PATTAI CHOORANAM (Internal) for CEGANA VATHAM (Cervical Spondylosis)
BKaruppannan0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Radiating pain to the upper limbs
- •With or without numbness in the upper limbs
- •Giddiness and Neck Stiffness
- •Patient who are willing for admission and stay in IPD or willing to attend OPD
- •Patients who are Willing to give blood samples for laboratory investigations
排除标准
- •Cervical rib
- •Spina bifida
- •Ankylosing spondylosis
- •Tuberculosis in spine
- •Cardiac disease
- •Other systemic illness
研究者
相似试验
已完成
2 期
Clinical trial on trial on eraippu erumal with yoga therapyCTRI/2019/06/019754S MUTHU VIGNESH40
已完成
2 期
CLINICAL TRIAL ON NEERIZHIVU[DIABETES MELLITUS] WITH YOGACTRI/2019/06/019749H JESIMA BARVEE40
已完成
2 期
Clinical trial on effectiveness of SIDDHAR YOGAM THERAPY and Siddha Kalpa Medicine Vilampazha karpam [Internal] in the management of â??Vatha Pitham [Systemic Hypertension]CTRI/2019/06/019956Joshi40
进行中（未招募）
1 期
A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR geneChemotherapy naïve, EGFR mutant non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001687-30-ESEuropean Thoracic Oncology Platform (ETOP)95
进行中（未招募）
1 期
A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR geneChemotherapy naïve, EGFR mutant non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001687-30-DEETOP IBCSG Partners Foundation95